During his 25-year career, Dr. Konstantinov has been a pioneer and leader in novel therapeutic development and manufacturing. He has been directly involved in the development and commercialization of multiple biotherapeutic modalities, including monoclonal antibodies, blood factors, enzymes, gene therapy vectors and exosomes produced by mammalian cells. He has published 60 peer reviewed papers and has more than 15 patents and patent applications. Over the last decade, he has pioneered the development of the end-to-end integrated continuous biomanufacturing technology, which is becoming a strategic trend for the biomanufacturing industry worldwide.
Currently Dr. Konstantinov is the Executive Vice President, Process Sciences & Manufacturing at Codiak BioSciences in Cambridge MA, where he is responsible for the development, scale up, manufacturing and characterization of the novel exosome-based biotherapeutics. At Codiak, Konstantin’s team has developed the first large scale exosome manufacturing process, currently operating in 2,000L fed-batch and 500L perfusion bioreactors.
Before joining Codiak in January 2016, he served as a Vice President of late-stage bioprocess and technology development at Genzyme/Sanofi. Prior to that, Konstantin worked for Bayer in Berkeley, CA, advancing to the position of Head of Process Sciences.
Dr. Konstantinov received his Ph.D. in Biochemical Engineering from Osaka University, Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware. Konstantin is the recipient of several prestigious awards, including the 1992 Award of the Japanese Society of Fermentation Technology, the 2004 ACS-BIOT Industrial Award (for Bayer Corp), the 2016 Cell Culture Engineering Award, and the 2017 Integrated Continuous Biomanufacturing Award.